|
1
|
Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH
and Lee JS: Prediction of cancer incidence and mortality in Korea,
2014. Cancer Res Treat. 46:124–130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
William WN Jr, Lin HY, Lee JJ, Lippman SM,
Roth JA and Kim ES: Revisiting stage IIIB and IV non-small cell
lung cancer: Analysis of the surveillance, epidemiology and end
results data. Chest. 136:701–709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Russell K, Healy B, Pantarotto J, Laurie
SA, MacRae R, Sabri E and Wheatley-Price P: Prognostic factors in
the radical nonsurgical treatment of stage IIIB non-small-cell lung
cancer. Clin Lung Cancer. 15:237–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laine AM, Westover KD and Choy H:
Radiation therapy as a backbone of treatment of locally advanced
non-small cell lung cancer. Semin Oncol. 41:57–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aupérin A, Le Péchoux C, Rolland E, Curran
WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus
R, Yamanaka T, et al: Meta-analysis of concomitant versus
sequential radiochemotherapy in locally advanced non-small-cell
lung cancer. J Clin Oncol. 28:2181–2190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hegyi G, Szigeti GP and Szász A:
Hyperthermia versus oncothermia: Cellular effects in complementary
cancer therapy. Evid Based Complement Alternat Med.
2013:6728732013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andocs G, Szasz O and Szasz A: Oncothermia
treatment of cancer: From the laboratory to clinic. Electromagn
Biol Med. 28:148–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer;
New York, NY: 2010
|
|
10
|
Coffey DS, Getzenberg RH and DeWeese TL:
Hyperthermic biology and cancer therapies: A hypothesis for the
‘Lance Armstrong effect’. JAMA. 296:445–448. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roti Roti JL: Cellular responses to
hyperthermia (40–46 degrees C): Cell killing and molecular events.
Int J Hyperthermia. 24:3–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Halperin EC, Brady LW, Perez CA and Wazer
DE: Perez and Brady's Principles and Practice of Radiation
Oncology. 6th. Lippincott Williams & Wilkins; Baltimore, MD:
2013
|
|
13
|
van der Zee J, González González D, van
Rhoon GC, van Dijk JD, van Putten WL and Hart AA: Dutch Deep
Hyperthermia Group: Comparison of radiotherapy alone with
radiotherapy plus hyperthermia in locally advanced pelvic tumours:
A prospective, randomised, multicentre trial. Lancet.
355:1119–1125. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sauer R, Creeze H, Hulshof M, Issels R and
Ott O: Interdisciplinary Working Group for Clinical Hyperthermia
(Atzelsberg Circle) of the German Cancer Society and the German
Society of Radiooncology: Concerning the final report
‘Hyperthermia: A systematic review’ of the Ludwig Boltzmann
Institute for Health Technology Assessment, Vienna, March 2010.
Strahlenther Onkol. 188:209–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wild C: Should hyperthermia be included in
the benefit catalogue for oncologic indications? Commercial
interests are presumed behind the editorial of R. Sauer et al.
Strahlenther Onkol. 189:81–86. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szasz A: Current status of oncothermia
therapy for lung cancer. Korean J Thorac Cardiovasc Surg. 47:77–93.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim MJ, Yeo SG, Kim ES, Min CK and Se An
P: Intensity-modulated stereotactic body radiotherapy for stage I
non-small cell lung cancer. Oncol Lett. 5:840–844. 2013.PubMed/NCBI
|
|
18
|
Yeo SG and Kim ES: Efficient approach for
determining four-dimensional computed tomography-based internal
target volume in stereotactic radiotherapy of lung cancer. Radiat
Oncol J. 31:247–251. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Curran WJ Jr, Paulus R, Langer CJ, Komaki
R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E,
Machtay M, Sause W and Cox JD: Sequential vs. concurrent
chemoradiation for stage III non-small cell lung cancer: Randomized
phase III trial RTOG 9410. J Natl Cancer Inst. 103:1452–1460. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bayman N, Blackhall F, McCloskey P, Taylor
P and Faivre-Finn C: How can we optimise concurrent
chemoradiotherapy for inoperable stage III non-small cell lung
cancer? Lung Cancer. 83:117–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Westermann AM, Jones EL, Schem BC, van der
Steen-Banasik EM, Koper P, Mella O, Uitterhoeve AL, de Wit R, van
der Velden J, Burger C, van der Wilt CL, et al: First results of
triple-modality treatment combining radiotherapy, chemotherapy and
hyperthermia for the treatment of patients with stage IIB, III and
IVA cervical carcinoma. Cancer. 104:763–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
